公开(公告)号：EP3064220A2

公开(公告)日：2016-09-07

申请号：EP16160525.8

申请日：2007-12-26

申请人： Emory University ,  Dana-Farber Cancer Institute, Inc. ,  President and Fellows of Harvard College

发明人： Ahmed, Rafi ,  Freeman, Gordon ,  Sharpe, Arlene ,  Amara, Rama

IPC分类号： A61K39/395 ,  A61K39/12 ,  C07K16/28 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00

摘要： PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In additions, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.

摘要翻译： 公开了可用于降低受试者中PD-1的表达或活性的PD-1拮抗剂。 使用这些PD-1拮抗剂与来自感染剂或肿瘤的抗原可以增强对感染剂或肿瘤细胞特异性的免疫应答。 因此，可以使用PD-1拮抗剂治疗感染的受试者，例如持续感染。 此外，可以使用PD-1拮抗剂治疗具有肿瘤的受试者。 在几个实例中，可以通过移植治疗有效量的识别感兴趣的抗原的活化T细胞并通过施用治疗有效量的PD-1拮抗剂来治疗受试者。

公开(公告)号：EP2133365A2

公开(公告)日：2009-12-16

申请号：EP09166886.3

申请日：2007-12-26

申请人： Emory University ,  DANA-FARBER CANCER INSTITUTE, INC. ,  President and Fellows of Harvard College

发明人： Ahmed, Rafi ,  Freeman, Gordon ,  Sharpe, Arlene ,  Amara, Rama

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K39/12 ,  A61P31/14 ,  A61P31/18 ,  A61P31/20 ,  A61P35/00

CPC分类号： C07K16/2827 ,  A61K39/12 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/5158 ,  A61K2039/5256 ,  C07K16/2818 ,  C12N2710/24143 ,  C12N2740/16011 ,  C12N2760/10011 ,  C12N2760/10034 ,  C12N2770/24211 ,  A61K2300/00

摘要： PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subj ects with infections, such as persistent infections can be treated using PD-1 antagonists. In additions, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.

摘要翻译： 公开了可用于降低受试者中PD-1的表达或活性的PD-1拮抗剂。 使用这些PD-1拮抗剂与来自感染剂或肿瘤的抗原可以增强对感染剂或肿瘤细胞特异性的免疫应答。 因此，可以使用PD-1拮抗剂治疗感染，如持续性感染的受治疗。 此外，可以使用PD-1拮抗剂治疗具有肿瘤的受试者。 在几个实例中，可以通过移植治疗有效量的识别感兴趣的抗原的活化T细胞并通过施用治疗有效量的PD-1拮抗剂来治疗受试者。

公开(公告)号：EP2397156A1

公开(公告)日：2011-12-21

申请号：EP11162681.8

申请日：2006-06-08

申请人： Dana-Farber Cancer Institute, Inc. ,  The Brigham and Women's Hospital, Inc. ,  Emory University ,  THE PRESIDENT & FELLOWS OF HARVARD COLLEGE

发明人： Barber, Daniel ,  Wherry, E. John ,  Freeman, Gordan ,  Sharpe, Arlene ,  Dorfman, David M. ,  Ahmed, Rafi

IPC分类号： A61K39/395 ,  G01N33/53 ,  C07K16/28

CPC分类号： C07K16/2803 ,  A61K31/713 ,  A61K38/1709 ,  A61K39/39 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55516 ,  A61K2039/55566 ,  A61K2039/572 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/70 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  G01N33/5011 ,  G01N33/505 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2800/26 ,  Y02A50/412 ,  Y02A50/467 ,  Y02A50/58

摘要： The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.